MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$65,709K
Free Cash flow
-$76,594K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of inve...
Accrued clinical trial costs
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Purchases of investments
Net accretion of available-for-s...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-06-30
Stock-based compensation
12,516
Net loss
-113,341
Prepaid expenses and other current assets
-833
Accrued personnel expenses
12,478
Deferred income
-125
Other accrued expenses
469
Accounts payable
-2,900
Unrealized foreign exchange loss
-415
Depreciation and amortization
664
Refundable income taxes
91
Net accretion of available-for-sale debt securities
-4,447
Unrecognized tax benefits
-2,070
Research and development tax credits receivable
493
Unbilled milestone receivable
0
Grants receivable
415
Accrued clinical trial costs
15,157
Change in operating lease right-of-use assets
-12
Net cash used in operating activities
-76,210
Proceeds from maturities of investments
225,047
Purchase of property and equipment
384
Purchase of other assets
26
Purchases of investments
89,991
Net cash provided by (used in) investing activities
134,646
Proceeds from issuance of common stock upon exercise of options and espp purchases
4,525
Net cash provided by financing activities
4,525
Effects of exchange rate changes on cash, cash equivalents and restricted cash
2,748
Net increase (decrease) in cash, cash equivalents and restricted cash
65,709
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of investments
$225,047K
Proceeds from issuance of
common stock upon...
$4,525K
Net cash provided by
(used in) investing...
$134,646K
Net cash provided by
financing activities
$4,525K
Effects of exchange rate
changes on cash, cash...
$2,748K
Canceled cashflow
$90,401K
Net increase
(decrease) in cash, cash...
$65,709K
Canceled cashflow
$76,210K
Purchases of investments
$89,991K
Purchase of property and
equipment
$384K
Purchase of other assets
$26K
Accrued clinical trial
costs
$15,157K
Stock-based compensation
$12,516K
Accrued personnel
expenses
$12,478K
Unrecognized tax benefits
-$2,070K
Prepaid expenses and
other current assets
-$833K
Depreciation and
amortization
$664K
Other accrued
expenses
$469K
Grants receivable
$415K
Unrealized foreign
exchange loss
-$415K
Refundable income taxes
$91K
Net cash used in
operating activities
-$76,210K
Canceled cashflow
$45,108K
Net loss
-$113,341K
Net accretion of
available-for-sale debt securities
-$4,447K
Accounts payable
-$2,900K
Research and development
tax credits...
$493K
Deferred income
-$125K
Change in operating
lease right-of-use...
-$12K
Buy us a coffee
iTeos Therapeutics, Inc. (ITOS)
iTeos Therapeutics, Inc. (ITOS)